Oryzon to Present ORY-2001 Preclinical efficacy data in Multiple Sclerosis animal model at ECTRIMS-2016 Annual Meeting
BARCELONA, SPAIN and CAMBRIDGE MA.
• World renowned Key Opinion Leader Dr. Xavier Montalban to join Oryzon’s Scientific Advisory Board
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today it will present efficacy data on its proprietary oral epigenetic drug ORY-2001 in a preclinical multiple sclerosis (MS) animal model.